As the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a ...

Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...

ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant ...

周一，ESSA Pharma (NASDAQ:EPIX)的股票评级和目标价格在Piper Sandler发生了重大变化。这家生物制药公司的评级从"增持"下调至"中性"，目标价格从之前的$15.00大幅调整至$2.00。此次降级是在ESSA Pharma宣布终止其药物候选者masofaniten的关键二期试验后做出的。

周五，Jones Trading将ESSA Pharma (NASDAQ:EPIX)的股票评级从"买入"下调至"持有"。这一调整是基于一项无效性分析，该分析显示公司主要药物候选者的试验结果不佳。 根据分析，在一项针对一线转移性去势抵抗性前列腺癌(mCRPC)的随机II期试验中，单独使用Xtandi的对照组比ESSA的masofaniten和Xtandi联合用药组更有效。 试验结果是导致评级下调的重 ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer ...

In a report released on November 1, Maury Raycroft from Jefferies downgraded ESSA Pharma (EPIX – Research Report) to a Hold, with a price ...

ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over ...

US clinical-stage firm ESSA Pharma has made the decision to terminate the Phase II clinical trial evaluating in a 2:1 ...

Essa Pharma's stock price plunged after the clinical-stage pharmaceutical company said it was throwing in the towel on its lead product candidate and exploring strategic alternatives. Shares of the ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...

ESSA Pharma Inc. (EPIX) announced that it has made the decision to terminate the Phase 2 clinical trial evaluating in a 2:1 ...